toxylact: a05aa02 ursodesoxycholic acid

The first professional lActological database in the word

Ursodeoxycholic acid (UDCA, ATC A05AA02) is a bile acid preparation used primarily for gallstone dissolution and chronic cholestatic liver disease; available data indicate negligible transfer into breast milk and compatibility with breastfeeding of healthy term infants.medpedia.framar+4

ATC class and pharmacological profile

Ursodeoxycholic acid belongs to ATC class A05AA “Bile acid preparations” within A05 “Bile and liver therapy,” with the specific code A05AA02. It is a hydrophilic secondary bile acid that reduces intestinal cholesterol absorption and the cholesterol saturation of bile, promoting gradual dissolution of cholesterol-rich gallstones. UDCA is naturally present in human bile in small amounts and exerts hepatoprotective and choleretic effects in chronic cholestatic conditions such as primary biliary cholangitis.wikipedia+4

Therapeutic indications (non‑lactation)

UDCA is indicated for dissolution of radiolucent cholesterol gallstones in patients with patent cystic duct and functioning gallbladder. It is used in primary biliary cholangitis and other chronic cholestatic liver diseases to improve biochemical markers and symptoms such as pruritus. Additional uses include biliary reflux gastritis, prophylaxis of gallstones during rapid weight loss, and hepatobiliary disorders associated with cystic fibrosis, according to product-specific information.snu.elsevierpure+3

Contraindications and precautions

UDCA is contraindicated in acute inflammatory diseases of the gallbladder and bile ducts, obstructive cholestasis, frequent biliary colic, and calcified gallstones. It should not be used when radiological imaging shows non-functioning gallbladder or stones that are radiopaque or unlikely to dissolve. In patients with advanced decompensated liver disease or severe hepatic impairment, cautious use and specialist supervision are required because evidence for benefit and safety is limited.mims+3

Adverse effects and toxicity profile

UDCA has a generally favorable safety profile at therapeutic doses, with diarrhea being the most frequent adverse effect, reported in 2–9% of patients treated for gallstone dissolution. Other adverse reactions include abdominal pain, exacerbation of pruritus in cholestatic patients, urticaria, weight gain, bloating, and rare thinning of hair; overdose may lead to significant diarrhea with fluid and electrolyte loss. Serious hepatotoxicity and systemic toxicity are rare in adults at standard doses, although UDCA has been reported ineffective and potentially unsafe in certain neonatal cholestatic conditions, underscoring the need for age‑ and indication‑specific evaluation.medpedia.framar+2

Pharmacodynamics and pharmacokinetics relevant to lactation

Pharmacodynamically, UDCA decreases intestinal cholesterol absorption and lowers biliary cholesterol concentration, thereby favoring dissolution of cholesterol gallstones. It is absorbed from the intestine, undergoes extensive enterohepatic circulation, and is excreted mainly in bile; only small fractions appear in systemic circulation and breast milk. In lactating women treated with UDCA 500–1500 mg/day, total bile acid concentrations in breast milk are identical to untreated controls and UDCA concentrations remain negligible (around 0.69 µmol/L), not contributing meaningfully to the neonatal bile acid pool.publications.cuni+4

Lactation safety: human data and expert sources

UDCA is detectable in human milk as a naturally occurring bile acid, and exogenous therapy adds only trace amounts, far below levels used therapeutically in infants. Prospective studies in lactating women with cholestatic liver disease have shown negligible UDCA transfer into milk, no reported adverse effects in breastfed infants, and normal growth and development during 1‑year follow‑up. Specialized breastfeeding safety resources classify UDCA as compatible or very low risk, noting non‑significant excretion into breast milk and absence of documented toxicity in exposed infants.ncbi.nlm.nih+4

Regulatory statements vs contemporary guidance

Some product labels and older regulatory texts state that it is not known whether UDCA passes into human milk and recommend avoiding use during lactation or weaning the infant if treatment is necessary. These cautions are based on limited early data and do not reflect more recent pharmacokinetic studies demonstrating negligible breast milk concentrations and reassuring infant outcomes. Contemporary hepatology guidelines now explicitly support continuation of UDCA during breastfeeding in women with primary biliary cholangitis and other cholestatic diseases when clinically indicated.midlandsmedicines+3

Toxicological‑lactological risk assessment (A05AA02)

From a toxicological perspective, UDCA has low systemic toxicity at standard adult doses, with adverse effects predominantly gastrointestinal and reversible, and serious events rare. Lactological assessment integrating pharmacokinetics, maternal benefit, and infant exposure suggests that UDCA is compatible with breastfeeding of full‑term, healthy infants, as infant exposure via milk is extremely low and well below therapeutic pediatric doses. Overall, for A05AA02 preparations, maternal treatment should generally be continued during lactation when clinically needed, with routine pediatric follow‑up and individualized consideration in premature or medically fragile infants.droracle+7

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.